ID

34335

Descrizione

Combination Treatment for Advanced Liver Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02149771

collegamento

https://clinicaltrials.gov/show/NCT02149771

Keywords

  1. 16/01/19 16/01/19 -
  2. 26/04/20 26/04/20 -
  3. 01/05/20 01/05/20 -
  4. 20/09/21 20/09/21 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

16 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Hepatocellular Carcinoma NCT02149771

Eligibility Hepatocellular Carcinoma NCT02149771

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
Descrizione

ID.1

Tipo di dati

boolean

(2) child-pugh classification grade a or b;
Descrizione

ID.2

Tipo di dati

boolean

(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
Descrizione

ID.3

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
Descrizione

ID.4

Tipo di dati

boolean

tumor invade the inferior vena cava, extrahepatic spread;
Descrizione

ID.5

Tipo di dati

boolean

contraindications for doxorubicin or oxaliplatin chemotherapy;
Descrizione

ID.6

Tipo di dati

boolean

any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
Descrizione

ID.7

Tipo di dati

boolean

renal failure,cardiac ejection fraction <50 %) or end-stage disease;
Descrizione

ID.8

Tipo di dati

boolean

patients who were not capable of cooperation during the procedure.
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Hepatocellular Carcinoma NCT02149771

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
(1) hepatocellular carcinoma(hcc) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased α-fetoprotein according to the american association for the study of liver diseases (aasld) guidelines and contrast-enhancing tumour thrombus within the main portal vein and one of the first-order branch on ct or mri;
boolean
ID.2
Item
(2) child-pugh classification grade a or b;
boolean
ID.3
Item
(3)eastern cooperative oncology group (ecog) performance status score of 2 or less.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
advanced liver disease (bilirubin levels >3 mg/dl, astor alt >5 × upper limit of normal);
boolean
ID.5
Item
tumor invade the inferior vena cava, extrahepatic spread;
boolean
ID.6
Item
contraindications for doxorubicin or oxaliplatin chemotherapy;
boolean
ID.7
Item
any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/l or prothrombin activity below 50 %);
boolean
ID.8
Item
renal failure,cardiac ejection fraction <50 %) or end-stage disease;
boolean
ID.9
Item
patients who were not capable of cooperation during the procedure.
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial